AU2016290197B2 - Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions - Google Patents

Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions Download PDF

Info

Publication number
AU2016290197B2
AU2016290197B2 AU2016290197A AU2016290197A AU2016290197B2 AU 2016290197 B2 AU2016290197 B2 AU 2016290197B2 AU 2016290197 A AU2016290197 A AU 2016290197A AU 2016290197 A AU2016290197 A AU 2016290197A AU 2016290197 B2 AU2016290197 B2 AU 2016290197B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
ocular
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016290197A
Other languages
English (en)
Other versions
AU2016290197A1 (en
Inventor
Achim Hans-Peter Krauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axerovision Inc
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of AU2016290197A1 publication Critical patent/AU2016290197A1/en
Application granted granted Critical
Publication of AU2016290197B2 publication Critical patent/AU2016290197B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016290197A 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions Ceased AU2016290197B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (2)

Publication Number Publication Date
AU2016290197A1 AU2016290197A1 (en) 2018-01-04
AU2016290197B2 true AU2016290197B2 (en) 2021-07-22

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016290197A Ceased AU2016290197B2 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Country Status (21)

Country Link
US (3) US10413535B2 (enExample)
EP (1) EP3319639B1 (enExample)
JP (2) JP6752276B2 (enExample)
KR (2) KR102440162B1 (enExample)
CN (1) CN107921136A (enExample)
AU (1) AU2016290197B2 (enExample)
BR (1) BR112018000112A2 (enExample)
CA (1) CA2989522C (enExample)
CL (1) CL2018000057A1 (enExample)
ES (1) ES2835274T3 (enExample)
HK (1) HK1247120A1 (enExample)
IL (2) IL256770B (enExample)
MA (2) MA42016A1 (enExample)
MX (1) MX385229B (enExample)
MY (1) MY187552A (enExample)
PL (1) PL3319639T3 (enExample)
RU (1) RU2018103940A (enExample)
TN (1) TN2017000538A1 (enExample)
UA (1) UA123728C2 (enExample)
WO (1) WO2017006272A1 (enExample)
ZA (1) ZA201708601B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592334A4 (en) * 2017-03-09 2020-12-16 Allysta Pharmaceuticals, Inc. PEPTIDES FOR DRY ILLNESS
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CA3145870A1 (en) * 2019-07-26 2021-02-04 Hampar L. Karageozian Peptides for treating non-exudative macular degeneration and other disorders of the eye
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation
US6867192B1 (en) * 1998-12-18 2005-03-15 Duncan Robert Armour Compounds useful in the treatment of inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867192B1 (en) * 1998-12-18 2005-03-15 Duncan Robert Armour Compounds useful in the treatment of inflammatory diseases
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, "An inhaled VLA-4 antagonist", EXPERT OPINION ON THERAPEUTIC PATENTS., GB, (2002-05-01), vol. 12, no. 5, doi:10.1517/13543776.12.5.755, ISSN 1354-3776, pages 755 - 757 *
Clara Andonian, IOVS, (2015-06-01), pages 1 - 2, URL: http://iovs.arvojournals.org/article.aspx?articleid=2334394, (2016-08-25) *
KRAUSS A. H. ET AL, "Effects of a novel integrin antagonist, GW559090, in an experimental dry eye model (Program number 2472)", IOVS, & ARVO, 2015, vol. 56, no. 7 *

Also Published As

Publication number Publication date
MX385229B (es) 2025-03-14
US20180200240A1 (en) 2018-07-19
PL3319639T3 (pl) 2021-03-08
KR20180041122A (ko) 2018-04-23
WO2017006272A1 (en) 2017-01-12
US20200405703A1 (en) 2020-12-31
IL280827A (en) 2021-04-29
BR112018000112A2 (pt) 2018-09-04
TN2017000538A1 (en) 2019-04-12
CA2989522A1 (en) 2017-01-12
RU2018103940A (ru) 2019-08-08
EP3319639A1 (en) 2018-05-16
KR20220062688A (ko) 2022-05-17
ZA201708601B (en) 2019-05-29
ES2835274T3 (es) 2021-06-22
MA42016A1 (fr) 2018-03-30
HK1247120A1 (zh) 2018-09-21
JP2018521126A (ja) 2018-08-02
US10413535B2 (en) 2019-09-17
AU2016290197A1 (en) 2018-01-04
IL256770B (en) 2021-02-28
US20200000786A1 (en) 2020-01-02
IL256770A (en) 2018-03-29
CN107921136A (zh) 2018-04-17
KR102440162B1 (ko) 2022-09-02
US10751334B2 (en) 2020-08-25
JP6752276B2 (ja) 2020-09-09
MA44935A1 (fr) 2019-08-30
CL2018000057A1 (es) 2018-06-22
JP2020121985A (ja) 2020-08-13
CA2989522C (en) 2022-10-18
MY187552A (en) 2021-09-29
EP3319639B1 (en) 2020-11-18
RU2018103940A3 (enExample) 2019-09-03
UA123728C2 (uk) 2021-05-26
MX2017017163A (es) 2018-08-09

Similar Documents

Publication Publication Date Title
US10751334B2 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
EP3525799B1 (en) Method for establishing, restoring, and preserving homeostasis of the ocular surface
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
KR20210093274A (ko) 자가항체-매개 안 질환의 치료 및 진단
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
WO2021260430A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US20200138806A1 (en) Nutlin-3a for Treatment of Proliferative Vitreoretinopathy
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
KR20220090725A (ko) 플루오로메톨론 아세테이트 및 올로파타딘 염산염을 포함하는 투명한 안과용 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired